
CNTA Stock Forecast & Price Target
CNTA Analyst Ratings
Bulls say
Centessa Pharmaceuticals PLC has a promising outlook due to its robust pipeline, specifically with the best-in-class potential of ORX750 for Narcolepsy Type 1, which could benefit from additional safety and efficacy data expected in early 2026. The company is financially well-positioned, having ended the second quarter of 2025 with approximately $405 million in cash, providing ample runway to support operations through mid-2027. Furthermore, the projected sales potential for ORX750 is estimated at around $3.6 billion, reflecting substantial upside potential from the pipeline's advancement and anticipated data outcomes.
Bears say
Centessa Pharmaceuticals's stock outlook is negatively impacted by concerns surrounding the high non-responder rates and late-day waning efficacy observed in related clinical programs, which may indicate broader issues within the OX2R class of treatments rather than being isolated to specific compounds. The Phase 2 data from the company reveals significant variability and potential suboptimal dose selection, further complicating the reliability of reported therapeutic effects and raising the probability of variable outcomes in real-world applications. Additionally, the inclusion of data from competing products appears to diminish the dose-response estimates for ORX750, raising further doubts about the potential of Centessa's pipeline assets in delivering anticipated results.
This aggregate rating is based on analysts' research of Centessa Pharmaceuticals PLC and is not a guaranteed prediction by Public.com or investment advice.
CNTA Analyst Forecast & Price Prediction
Start investing in CNTA
Order type
Buy in
Order amount
Est. shares
0 shares